Clin Kidney J 2022;15(8);1593-600 doi: 10.1093/ckj/sfac096
Up to 43% of patients with T2D develop CKD, and albuminuria appears early in 17–26%. Semaglutide has shown nephroprotective effects in previous studies, but its efficacy and safety in patients with CKD and T2D have been rarely studied. This retrospective study in Spain looked at 122 patients over 12 months in real-world practice.
Overall, 57% of patients achieved HbA1c <7%, and 59% had lost more than 5% of their body weight after 12 months. There were also improvements in renal parameters, and blood pressure reductions greater than those seen in the SUSTAIN-6 trial.